Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07GTW
|
||||
| Former ID |
DIB002811
|
||||
| Drug Name |
Cyclic pyranopterin monophosphate
|
||||
| Synonyms |
CPMP; CPMP (molybdenum cofactor deficiency), Alexion; CPMP (molybdenum cofactor deficiency), Orphatec
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Encephalopathy [ICD10:G93.4] | Phase 2 | [1] | ||
| Company |
Orphatec Pharmaceuticals GmbH
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C10H14N5O8P
|
||||
| Canonical SMILES |
OP1(=O)OCC2OC3Nc4nc([nH]c(=O)c4NC3C(O)(O)C2O1)N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Xanthine dehydrogenase/oxidase | Target Info | Cofactor | [2] | |
| BioCyc Pathway | Purine nucleotides degradation | ||||
| Urate biosynthesis/inosine 5'-phosphate degradation | |||||
| Guanosine nucleotides degradation | |||||
| Adenosine nucleotides degradation | |||||
| Retinoate biosynthesis II | |||||
| KEGG Pathway | Purine metabolism | ||||
| Caffeine metabolism | |||||
| Drug metabolism - other enzymes | |||||
| Metabolic pathways | |||||
| Peroxisome | |||||
| PANTHER Pathway | Adenine and hypoxanthine salvage pathway | ||||
| Purine metabolism | |||||
| PathWhiz Pathway | Caffeine Metabolism | ||||
| Purine Metabolism | |||||
| Reactome | Purine catabolism | ||||
| WikiPathways | Oxidative Stress | ||||
| Effects of Nitric Oxide | |||||
| Metabolism of nucleotides | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02047461) Safety & Efficacy Study of ALXN1101 in Pediatric Patients With MoCD Type A Currently Treated With rcPMP. U.S. National Institutes of Health. | ||||
| REF 2 | Successful treatment of molybdenum cofactor deficiency type A with cPMP. Pediatrics. 2010 May;125(5):e1249-54. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.